{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:15:14Z","timestamp":1793502914759,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T00:00:00Z","timestamp":1518566400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["15\/576"],"award-info":[{"award-number":["15\/576"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s00223-018-0404-6","type":"journal-article","created":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T05:32:05Z","timestamp":1518586325000},"page":"55-61","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["Bone Loss After Romosozumab\/Denosumab: Effects of Bisphosphonates"],"prefix":"10.1007","volume":"103","author":[{"given":"Anne M.","family":"Horne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borislav","family":"Mihov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6021-5458","authenticated-orcid":false,"given":"Ian R.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,14]]},"reference":[{"key":"404_CR1","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK et al (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972\u2013980","journal-title":"J Clin Endocrinol Metab"},{"key":"404_CR2","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","volume":"43","author":"PD Miller","year":"2008","unstructured":"Miller PD, Bolognese MA, Lewiecki EM et al (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43:222\u2013229","journal-title":"Bone"},{"key":"404_CR3","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","volume":"27","author":"AW Popp","year":"2016","unstructured":"Popp AW, Zysset PK, Lippuner K (2016) Rebound-associated vertebral fractures after discontinuation of denosumab\u2014from clinic and biomechanics. Osteoporos Int 27:1917\u20131921","journal-title":"Osteoporos Int"},{"issue":"suppl","key":"404_CR4","first-page":"S408","volume":"31","author":"AW Popp","year":"2016","unstructured":"Popp AW, Buffat H, Senn C et al. (2016) Rebound-associated bone loss after non-renewal of long-term denosumab treatment offsets 10-year gains at the total hip within 12 months. J Bone Miner Res 31(suppl):S408","journal-title":"J Bone Miner Res"},{"key":"404_CR5","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","volume":"28","author":"MR McClung","year":"2017","unstructured":"McClung MR, Wagman RB, Miller PD et al (2017) Observations following discontinuation of long-term denosumab therapy. Osteoporos Int 28:1723\u20131732","journal-title":"Osteoporos Int"},{"key":"404_CR6","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","volume":"27","author":"B Aubry-Rozier","year":"2016","unstructured":"Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D et al (2016) Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int 27:1923\u20131925","journal-title":"Osteoporos Int"},{"key":"404_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3110","author":"AD Anastasilakis","year":"2017","unstructured":"Anastasilakis AD, Polyzos SA, Makras P et al (2017) Clinical features of 24 patients with rebound-associated vertebral fractures following denosumab discontinuation: systematic review and additional cases. J Bone Miner Res. \n                    https:\/\/doi.org\/10.1002\/jbmr.3110","journal-title":"J Bone Miner Res"},{"key":"404_CR8","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s00198-015-3459-5","volume":"27","author":"AD Anastasilakis","year":"2016","unstructured":"Anastasilakis AD, Makras P (2016) Multiple clinical vertebral fractures following denosumab discontinuation. Osteoporos Int 27:1929\u20131930","journal-title":"Osteoporos Int"},{"key":"404_CR9","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/jc.2017-00096","volume":"102","author":"O Lamy","year":"2017","unstructured":"Lamy O, Gonzalez-Rodriguez E, Stoll D et al (2017) Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J Clin Endocrinol Metab 102:354\u2013358","journal-title":"J Clin Endocrinol Metab"},{"issue":"supp","key":"404_CR10","first-page":"S32","volume":"31","author":"JP Brown","year":"2016","unstructured":"Brown JP, Ferrari S, Gilchrist N et al (2016) Discontinuation of denosumab and associated fracture incidence: analysis from FREEDOM and its extension. J Bone Miner Res 31(supp):S32\u2013S33","journal-title":"J Bone Miner Res"},{"key":"404_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","volume":"23","author":"N Freemantle","year":"2012","unstructured":"Freemantle N, Satram-Hoang S, Tang ET et al (2012) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23:317\u2013326","journal-title":"Osteoporos Int"},{"key":"404_CR12","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00223-017-0288-x","volume":"101","author":"IR Reid","year":"2017","unstructured":"Reid IR, Horne AM, Mihov B et al (2017) Bone loss after denosumab: only partial protection with zoledronate. Calcif Tissue Int 101:371\u2013374","journal-title":"Calcif Tissue Int"},{"key":"404_CR13","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1007\/s00198-017-4108-y","volume":"28","author":"T Lehmann","year":"2017","unstructured":"Lehmann T, Aeberli D (2017) Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures. Osteoporos Int 28:3067\u20133068","journal-title":"Osteoporos Int"},{"key":"404_CR14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s40259-017-0229-2","volume":"31","author":"IR Reid","year":"2017","unstructured":"Reid IR (2017) Targeting sclerostin in postmenopausal osteoporosis: focus on romosozumab and blosozumab. Biodrugs 31:289\u2013297","journal-title":"Biodrugs"},{"key":"404_CR15","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412\u2013420","journal-title":"N Engl J Med"},{"key":"404_CR16","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543","journal-title":"N Engl J Med"},{"key":"404_CR17","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427","journal-title":"N Engl J Med"},{"key":"404_CR18","first-page":"S53","volume":"29","author":"MR McClung","year":"2014","unstructured":"McClung MR, Chines A, Brown JP et al (2014) Effects of 2 years of treatment with romosozumab followed by 1 year ofdenosumab or placebo in postmenopausal women with low bone mineral density. J Bone Miner Res 29:S53","journal-title":"J Bone Miner Res"},{"key":"404_CR19","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/jbmr.251","volume":"26","author":"R Eastell","year":"2011","unstructured":"Eastell R, Christiansen C, Grauer A et al (2011) Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 26:530\u2013537","journal-title":"J Bone Miner Res"},{"key":"404_CR20","doi-asserted-by":"publisher","first-page":"E1130-E1136","DOI":"10.1503\/cmaj.161207","volume":"189","author":"A Grey","year":"2017","unstructured":"Grey A, Bolland MJ, Horne A et al (2017) Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial. CMAJ 189:E1130-E1136","journal-title":"CMAJ"},{"key":"404_CR21","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1210\/jc.2016-1801","volume":"101","author":"PD Miller","year":"2016","unstructured":"Miller PD, Pannacciulli N, Brown JP et al (2016) Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab 101:3163\u20133170","journal-title":"J Clin Endocrinol Metab"},{"key":"404_CR22","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"404_CR23","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"404_CR24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bone.2017.03.006","volume":"98","author":"BZ Leder","year":"2017","unstructured":"Leder BZ, Tsai JN, Jiang LA et al (2017) Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: the Denosumab and Teriparatide Follow-up study (DATA-Follow-up). Bone 98:54\u201358","journal-title":"Bone"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-018-0404-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-018-0404-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-018-0404-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T19:49:38Z","timestamp":1550087378000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-018-0404-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,14]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["404"],"URL":"https:\/\/doi.org\/10.1007\/s00223-018-0404-6","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,14]]},"assertion":[{"value":"22 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"IRR has received research grants and honoraria from Amgen, Novartis, Merck, and Lilly. AMH and BM have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by our regional ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}